Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics

Journal of Managed Care Pharmacy

Volumn 18, Issue 9 A, 2012, Pages 676-689

  Sikirica, Vanja ^a   Pliszka, Steven R ^c   Betts, Keith A ^b   Hodgkins, Paul ^a   Samuelson, Tom ^b   Xie, Jipan ^b   Erder, M Haim ^a   Dammerman, Ryan ^a   Robertson, Brigitte ^a   Wu, Eric Q ^b  

^a SHIRE   (United States)

^b ANALYSIS GROUP   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ARIPIPRAZOLE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLONIDINE; CLOZAPINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; GUANFACINE; LISDEXAMFETAMINE; METHYLPHENIDATE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PRESCRIPTION DRUG; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; DRUG WITHDRAWAL; EMERGENCY TREATMENT; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; ICD-9-CM; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; OUTCOME ASSESSMENT; OUTPATIENT CARE; PRESCHOOL CHILD; SCHOOL CHILD; UNITED STATES;

EID: 84872449768     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2012.18.9.676     Document Type: Article

References (35)

1. Pastor PN, Reuben CA. Diagnosed attention deficit hyperactivity disorder and learning disability: United States, 2004-2006. Vital Health Stat 10. 2008;(237):1-14.
2. Centers for Disease Control and Prevention. Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children- United States, 2003 and 2007. MMWR Morb Mortal Wkly Rep. 2010;59(44);1439-43.
3. Swensen AR, Birnbaum HG, Secnik K, et al. Attention-deficit/hyperactivity disorder: increased costs for patients and their families. J Am Acad Child Adolesc Psychiatry. 2003;42(12):1415-23.
4. Pelham WE, Foster EM, Robb JA, et al. The economic impact of attentiondeficit/ hyperactivity disorder in children and adolescents. Ambul Pediatr. 2007;7(Suppl 1):S121-S131.
5. Guevara J, Lozano P, Wickizer T, et al. Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108(1):71-78.
6. Swensen A, Birnbaum HG, Ben Hamadi R, et al. Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients. J Adolesc Health. 2004;35(4):346.e1-9.
7. Burd L, Klug MG, Coumbe MJ, et al. Children and adolescents with attention deficit-hyperactivity disorder: 1. Prevalence and cost of care. J Child Neurol. 2003;18(8):555-61.
8. Leibson CL, Katusic SK, Barbaresi WJ, et al. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA. 2001;285(1):60-66.
9. Mandell DS, Guevara JP, Rostain AL, Hadley TR. Economic grand rounds: medical expenditures among children with psychiatric disorders in a Medicaid population. Psychiatr Serv. 2003;54(4):465-67.
10. Chan E, Zhan C, Homer CJ. Health care use and costs for children with attention-deficit/hyperactivity disorder: national estimates from the medical expenditure panel survey. Arch Pediatr Adolesc Med. 2002;156(5):504-11.
11. Harman JS, Childs GE, Kelleher KJ. Mental health care utilization and expenditures by children in foster care. Arch Pediatr Adolesc Med. 2000;154(11):1114-17.
12. Jensen PS, Garcia JA, Glied S, et al. Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD. Am J Psychiatry. 2005;162(9):1628-36.
13. Olfson M. New options in the pharmacological management of attention-deficit/hyperactivity disorder. Am J Manag Care. 2004;10(4 Suppl): S117-S124.
14. Kratochvil CJ. New ADHD treatment options on the horizon. Advanced Studies in Medicine. 2002;2(25):915-18.
15. Cooper WO, Arbogast PG, Ding H, Hickson GB, Fuchs DC, Ray WA. Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr. 2006;6(2):79-83. Available at: http://psychrights.org/articles/ KidAtypicalPrescribingTrends.pdf. Accessed November 27, 2012.
16. Pathak P, West D, Martin BC, Helm ME, Henderson C. Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005. Psychiatr Serv. 2010;61(2):123-29.
17. Weiss M, Panagiotopoulos C, Giles L, et al. A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic. J Child Adolesc Psychopharmacol. 2009;19(5):575-82.
18. Zuvekas SH. Prescription drugs and the changing patterns of treatment for mental disorders, 1996-2001. Health Aff (Millwood). 2005;24(1)195-205.
19. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011;20(2):177-84.
20. Maglione M, Ruelaz Maher A, Hu J. Off-label use of atypical antipsychotics: an update. Comparative Effectiveness Review No. 43. (Prepared by the Southern California/RAND Evidence-based Practice Center under Contract No. HHSA290-2007-10062-1.) AHRQ Publication No. 11-EHC087-EF. Rockville, MD: Agency for Healthcare Research and Quality. September 2011. Available at: http://www.effectivehealthcare.ahrq.gov/search-forguides-reviews-and-reports/?pageaction=displayproduct&productid=786. Accessed November 27, 2012.
21. Findling RL, Steiner H, Weller EB. Use of antipsychotics in children and adolescents. J Clin Psychiatry. 2005;66(Suppl 7):S29-S40.
22. Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention deficit/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry. 2007;46(5):558-65.
23. Correia Filho AG, Bodanese R, Silva TL, et al. Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation. J Am Acad Child Adolesc Psychiatry. 2005;44(8):748-55.
24. Tramontina S, Zeni CP, Ketzer CR, Pheula GF, Narvaez J, Rohde LA. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry. 2009;70(5):756-64.
25. Zeni CP, Tramontina S, Ketzer CR, et al. Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized cossover trial. J Child Adolesc Psychopharmacol. 2009;19(5):553-61.
26. Kutcher S, Aman M, Brooks SJ, et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol. 2004;14(1):11-28.
27. Bergstralh EJ, Kosanke JL, Jacobsen SJ. Software for optimal matching in observational studies. Epidemiology. 1996;7(3):331-32.
28. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55. Available at: http://www.biostat.jhsph.edu/~jfeder/Journal_Club_files/ Biometrika%201983%20Rosenbaum.pdf. Accessed November 27, 2012.
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000.
30. U.S. Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Available at: http://www.bls.gov/cpi/. Accessed November 27, 2012.
31. Christensen L, Sasané R, Hodgkins P, et al. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin. 2010;26(4):977-89.
32. Erder MH, Signorovitch JE, Setyawan J, et al. Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity. J Med Econ. 2012;15(6):1078-87.
33. Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2011;21(6):517-35.
34. Andrade SE, Lo JC, Roblin D, et al. Antipsychotic medication use among children and risk of diabetes mellitus. Pediatrics. 2011;128(6):1135-41.
35. Pringsheim T, Lam D, Ching H, Patten S. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Saf. 2011;34(8):651-68.